Federation des caisses Desjardins du Quebec’s Traws Pharma TRAW Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$414	Buy	+500	New	+$689	﹤0.01%	2886

Other funds holding TRAW

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ABG

Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's TRAW Position: Q2 2026 in Review

Federation des caisses Desjardins du Quebec opened a new position in Traws Pharma (TRAW) in Q2 2026: 500 shares worth $414. The stake represents ﹤0.01% of the portfolio and ranks #2886 among its holdings.

35 funds tracked by Wall St. Rank hold TRAW as of Q2 2026.

Federation des caisses Desjardins du Quebec held 500 shares of Traws Pharma worth $414 as of Q2 2026.
Traws Pharma was a new Federation des caisses Desjardins du Quebec position in Q2 2026.
Traws Pharma made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q2 2026, its #2886 holding.
35 funds tracked by Wall St. Rank held Traws Pharma as of Q2 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q2 2026, filed 14 Aug 2026.